Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

September

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

16

Exagen Inc. Expands Coverage with Alivio Health

Partnership to provide more accurate diagnostic testing with AVISE® CTD and AVISE® Lupus SAN...

9

Exagen and Queen Mary University of London Announce Exclusive License and Collaboration Agreement

Collaboration to develop novel patented molecular signatures for rheumatoid arthritis biologic therapeutic selection SAN...

9

Exagen Inc. Reports Second Quarter 2021 Results

Quarterly Records: Total Revenue, AVISE® CTD Revenue and Volumes, Ordering Healthcare Providers and Adopters...

4

Exagen Inc., Allegheny Health Network Research Institute, and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests

The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis,...

29

Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases

Collaboration with Emory University will utilize the AVISE® testing portfolio SAN DIEGO, March 29, 2021 (GLOBE...

21

Exagen Inc. Partners with Boston’s Tufts Medical Center to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the...

10

Exagen Inc. Reports Third Quarter 2020 Results

Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing...

23

Exagen Appoints Wendy Johnson to Board of Directors

Additional independent board member will also serve on Audit Committee SAN DIEGO, Sept. 23, 2020 (GLOBE...

3

Exagen Inc. Announces Clinical Trial Conducted at Major Academic Center in Distinguishing Type 1 and Type 2 Lupus

Duke Lupus Clinic is focused on diagnosing, treating, and providing expert care to patients living...

9

Exagen Inc. Partners with Three California Medical Groups to Offer AVISE Testing as Covered In-Network Benefit for Their Patients

AVISE testing can facilitate improved care through the differential diagnosis, prognosis, management, and therapeutic...

18

Exagen to Present at Cowen and Company 40th Annual Healthcare Conference

Live webcast and replay links will be available from the investor relations section of...

Recent developments

News

September

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

May

16

Exagen Inc. Expands Coverage with Alivio Health

January

9

Exagen and Queen Mary University of London Announce Exclusive License and Collaboration Agreement

August

9

Exagen Inc. Reports Second Quarter 2021 Results

May

4

Exagen Inc., Allegheny Health Network Research Institute, and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests

March

29

Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases

January

21

Exagen Inc. Partners with Boston’s Tufts Medical Center to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

November

10

Exagen Inc. Reports Third Quarter 2020 Results

September

23

Exagen Appoints Wendy Johnson to Board of Directors

June

3

Exagen Inc. Announces Clinical Trial Conducted at Major Academic Center in Distinguishing Type 1 and Type 2 Lupus

March

9

Exagen Inc. Partners with Three California Medical Groups to Offer AVISE Testing as Covered In-Network Benefit for Their Patients

February

18

Exagen to Present at Cowen and Company 40th Annual Healthcare Conference